← Issue №19/ week of Nov 8, 2026/Pancreas/Biliary

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin-gemcitabine-durvalumab in advanced biliary tract cancers.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary retrospective · n=1,382 · Nov 4, 2026 · J Gastroenterology · IF 5.7

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin-gemcitabine-durvalumab in advanced biliary tract cancers.

New evidencecholangiocarcinomabiliary stricturepancreatic cancer
Clinical takeawayReal-world outcomes support CGD as the first-line standard in advanced biliary tract cancer, including for patients outside TOPAZ-1 eligibility, whose survival was similar to the trial arm.
What it foundOverall survival in 1,382 real-world patients from 55 centres was longer than in the reconstructed TOPAZ-1 CGD arm (HR 0.83, p=0.012; calibrated HR 0.84); trial-eligible patients did better than the trial population (HR 0.76) and trial-ineligible patients similarly (HR 0.98).
ContextRetrospective comparison against reconstructed trial data; the larger differences for ECOG PS 0 and locally advanced disease are exploratory.
Reinforcessuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Camera S … Casadei-Gardini A · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues